Cargando…
Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab
BACKGROUND: Hemolytic-uremic syndrome (HUS) presents with hemolytic anemia, thrombocytopenia, and thrombotic microangiopathy of the kidney and usually results from Shiga-toxin induced activation of the alternative complement pathway. Gastroenteritis is a common feature of the Shiga-toxin producing E...
Autores principales: | Webb, Tennille N., Griffiths, Heidi, Miyashita, Yosuke, Bhatt, Riha, Jaffe, Ronald, Moritz, Michael, Hofer, Johannes, Swiatecka-Urban, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849479/ https://www.ncbi.nlm.nih.gov/pubmed/27135055 http://dx.doi.org/10.9734/IJMPCR/2015/18771 |
Ejemplares similares
-
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017) -
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021) -
The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)